secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001140361-25-042304
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys Q3 sales up 31% to $729K; FDA clears FemBloc final pivotal trial; $12M financing extends runway
--------------------------------------------------------------------------------

- Net loss $4.19M ($0.10/sh) vs $5.41M ($0.24/sh) a year ago on lower R&D spend.
- Sales rose 31.4% YoY to $729,394, driven by FemBloc product sales.
- FDA IDE approval to commence final phase of FemBloc pivotal trial for U.S. approval.
- Closed $12M secured convertible note offering with warrants for up to $58M total potential funding.
- Cash $4.6M at Q3 end; with recent financing, runway extended into September 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036125042304/0001140361-25-042304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036125042304/ef20059086_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-042304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer